Avoro Capital Advisors
Avoro Capital Advisors reported 30 stocks worth $9.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (15.4%), ASND (11.9%) and KRYS (9.9%). Compared with Q2 2026, the fund opened new positions in DMRA, ABVX and SCTX, added to AVTX and trimmed UTHR, ASND and ARWR.
Latest filing: what Avoro Capital Advisors did in Q3 2026
vs Q2 2026
AVTX+$681K+2%
- Galecto Inc$98.4M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() UTHR United Therapeutics Corp Del | $1.5B | 15.4% | 2.8M | −22K (−1%) | 8 of 8 | |
| 2 | ![]() ASND Ascendis Pharma A/s | $1.2B | 11.9% | 5M | −61K (−1%) | 2 of 8 | |
| 3 | ![]() KRYS Krystal Biotech Inc | $961M | 9.9% | 2.9M | No change | 8 of 8 | |
| 4 | ![]() ARGX Argenx SE | $959M | 9.9% | 1M | No change | 8 of 8 | |
| 5 | ![]() MDGL Madrigal Pharmaceuticals Inc | $924M | 9.5% | 1.8M | No change | 8 of 8 | |
| 6 | ![]() KYMR Kymera Therapeutics Inc | $836M | 8.6% | 7.5M | No change | 8 of 8 | |
| 7 | ![]() ARWR Arrowhead Pharmaceuticals in | $720M | 7.4% | 11M | −356K (−3%) | 8 of 8 | |
| 8 | ![]() RVMD Revolution Medicines Inc | $440M | 4.5% | 2.1M | −152K (−7%) | 4 of 8 | |
| 9 | ![]() CYTK Cytokinetics Inc | $323M | 3.3% | 4.9M | −100K (−2%) | 3 of 8 | |
| 10 | ![]() DFTX Definium Therapeutics Inc | $268M | 2.8% | 7M | −139K (−2%) | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
GALECTO INC | $98.4M | 3.8M |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Avoro Capital Advisors 13F FAQ
What does Avoro Capital Advisors own?
Avoro Capital Advisors reported 30 stocks worth $9.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (15.4%), ASND (11.9%) and KRYS (9.9%). The table above lists every position in the filing (the top 10 without an account).
What did Avoro Capital Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 5 new positions, 1 added to, 15 trimmed and 1 sold out. New positions include DMRA, ABVX and SCTX.
When will Avoro Capital Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Avoro Capital Advisors's portfolio worth?
The Q3 2026 filing reports $9.7B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.














